Cipla Q3 profit seen up 13%; generic Renvela, Pulmicort, Dacogen may drive US biz

Drug major Cipla is likely to report 13.5 percent growth year-on-year in profit at Rs 425.5 crore for quarter ended December 2017.

Revenue from operations during the quarter is seen rising 12.4 percent to Rs 4,099.4 crore compared to Rs 3,647.2 crore in year-ago, according to average of estimates of analysts polled by CNBC-TV18.

Operating profit is expected to increase 16.7 percent year-on-year to Rs 791 crore and margin may expand 70 basis points to 19.3 percent in Q3.

Exports may drive growth, rising around 18-19 percent YoY. US business may be driven by generic Renvela, Pulmicort and Dacogen. However, US pricing pressure impacting performance would be watched.

Domestic business is likely bounce back post GST could be offset by seasonality. Other markets like South Africa, Europe and Emerging Markets may grow upto 30 percent YoY.